Business Context and Reporting Period
Company: Prothena Corporation plc (formerly Neotope Corporation plc)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2012
Business Overview: Prothena is a biotechnology company focused on discovering and developing novel monoclonal antibodies targeting protein misfolding and cell adhesion diseases. Key indications include amyloidosis, Parkinson's disease, inflammatory diseases, and metastatic cancers.
Corporate Status: The company separated from Elan Corporation, plc on December 21, 2012, and began trading on the NASDAQ Global Market under the symbol "PRTA". Prior to this date, financial results were presented on a "carve-out" basis from Elan's consolidated statements.
Key Financial Metrics
| Financial Metric (in thousands) | 2012 | 2011 | 2010 |
|---|---|---|---|
| Revenue | $2,658 | $507 | $1,243 |
| Net Loss | $(41,411) | $(29,670) | $(12,482) |
| Research & Development Expenses | $34,139 | $24,172 | $9,787 |
| General & Administrative Expenses | $9,929 | $5,579 | $3,618 |
| Cash and Cash Equivalents (Year End) | $124,860 | $0 | $0 |
| Total Assets | $129,283 | $3,618 | $3,278 |
| Total Liabilities | $2,799 | $10,054 | $3,249 |
Note: Cash balances for 2011 and 2010 are reported as zero because the company operated as part of Elan and did not maintain separate cash accounts prior to the separation.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 424% to $2.7 million in 2012 compared to $0.5 million in 2011, driven by an expanded scope of R&D services provided to Elan.
- Increased Operating Loss: Net loss widened to $41.4 million in 2012 from $29.7 million in 2011. This was primarily due to a 41% increase in R&D expenses ($34.1 million) and a 78% increase in G&A expenses ($9.9 million).
- Liquidity Transformation: Following the separation and distribution, the company received a net cash investment of $99.0 million from Elan and an additional $26.0 million from Elan's purchase of 18% of outstanding shares. This resulted in year-end cash of $124.9 million, compared to no standalone cash position in prior years.
- Share Structure: As of December 31, 2012, the company had 17,679,182 ordinary shares outstanding. Prior to the separation, no shares were outstanding.
Guidance, Outlook, and Risks
Outlook and Pipeline
- Clinical Trials: The company plans to initiate Phase 1 clinical trials for its lead programs: NEOD001 (amyloidosis) in H1 2013, PRX002 (Parkinson's) in 2014, and PRX003 (inflammatory disease/cancer) in 2015.
- Capital Needs: Management expects current cash resources to fund operations for at least the next 12 months. However, substantial additional capital will be required to advance clinical trials and commercialize products. Future funding may come from equity offerings, debt, or strategic alliances.
- Profitability: The company anticipates incurring losses for the foreseeable future and does not expect to achieve profitability until products are successfully commercialized, if ever.
Key Risks and Contingencies
- Dependence on Elan: Historically, all revenue was derived from R&D services to Elan. While a new R&D Services Agreement was signed, the company faces risks related to the transition to a standalone entity.
- Manufacturing Dependence: Prothena relies entirely on Boehringer Ingelheim for the manufacturing of clinical supplies for NEOD001.
- Regulatory and Development Risk: No drug candidates are currently in clinical trials. Success depends on preclinical data, regulatory approvals, and clinical trial outcomes, all of which are highly uncertain.
- Tax Status: The company expects to be classified as a Passive Foreign Investment Company (PFIC), which could result in adverse U.S. federal income tax consequences for U.S. shareholders.
- Intellectual Property: The company relies on patents and licenses (including from the University of Tennessee and Elan affiliates) to protect its technology. Litigation or failure to secure patents could harm the business.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $124.9 million cash balance against the projected costs of initiating Phase 1 trials for NEOD001 in 2013.
- Revenue Sustainability: Assess the terms of the new Research and Development Services Agreement with Elan to determine if revenue from related-party services will continue or decline post-separation.
- Manufacturing Agreements: Review the specific terms and capacity guarantees with Boehringer Ingelheim regarding NEOD001 supply.
- Intellectual Property Portfolio: Confirm the status of key patents (e.g., US Patent No. 7,928,203 expiring 2029) and the terms of the exclusive license with the University of Tennessee.
- PFIC Implications: Consult tax advisors regarding the specific tax consequences of the company's expected PFIC status for U.S. investors.